ELVN News
Archived Headlines
- Phase 2 rare disease biotech Imara prices upsized IPO at $16 low end 03/11/20
- How the coronavirus has reshaped the 2020 IPO timeline 03/10/20
- How the coronavirus has reshaped the 2020 IPO timeline 03/10/20
- US IPO Week Ahead: One biotech takes on a turbulent IPO market 03/06/20
- Genetic disorder biotech Imara sets terms for $76 million IPO 03/03/20
See more
2020 biotech IPOs now average an 80% return from their offer price
The 2020 US biotech IPO class closed Wednesday with an 80% average return from the offering price, a historic run-up for the year's 23 development-stage drug developers. The group has averaged a 36% pop on day one, and then 35% from there. Biotechs make up 70%...read more
US IPO Week Ahead: Another biotech plans to take on the IPO market
Biotechs are back as another early stage biotech, Keros Therapeutics (KROS), plans to take on the IPO market in the week ahead, following last week's successful debut of Zentalis Pharmaceuticals (ZNTL). ...read more
Post-IPO filings reveal significant insider buying on Imara
Rare disease biotech Imara (IMRA) has traded in a surprisingly tight range since its March IPO, even as the biotech industry sees drastic price swings. Post-IPO filings may reveal why: Existing shareholders took down a significant portion of...read more
US IPO Weekly Recap: 1 biotech prices ahead of the IPO market’s quarantine
As a rule, if March Madness gets canceled, then the IPO window is closed. Remarkably, one biotech pulled off an IPO this week, along with a blank check company. Outside of a few more SPACs, the IPO market may essentially shut down for months, as...read more